Encysive Restructures Agreement With Revotar

Encysive Pharmaceuticals announced the signing of a new licensing and related agreements with Revotar Biopharmaceuticals AG, the Company's majority-owned German subsidiary, regarding bimosiamose and certain follow-on compounds. Revotar's other stockholders will contribute additional capital to Revotar to fund its ongoing operations, thereby reducing Encysive's ownership to approximately 14 percent. Encysive will license the worldwide rights to bimosiamose and receive substantial royalties on future revenues from the commercialization or licensing of this compound and certain follow-on compounds by Revotar.

Yahoo News (http://au.biz.yahoo.com/050426/21/47r6.html)